Diabetes mellitus is most common health burden especially in elderly.Sarcopenia is one of the complications which is been neglected, eventually can lead to poor quality of life. Recently WHO recognized sarcopenia as a disease. There is no definite treatment for it. Resistance training is proved to ameliorate sarcopenia to some extent. Diagnosing sarcopenia at preclinical stage would be required to establish preventive measures. There is no definite criteria to diagnose sarcopenia in India. The most accepted criteria to diagnose sarcopenia is EWGSOP which includes many tests and some are quite expensive. This is one of the reasons of neglecting the diagnosis. Defining a biomarker panel which can easily detect sarcopenia would be beneficial to detect sarcopenia at an early stage . Here we hypothes that after resistance training  there will be a differential expression of muscle specific biomarkers and myomiRNAs.The objective of the study is to compare the predictive value of biomarkers in diagnosing sarcopenia among type 2 diabetes mellitus patients and to compare the alterations in biomarkers before and after resistance training program among type 2 diabetic subjects with sarcopenia. It will be an analytical cohort study. The sample size calculated is 20.The subjects will be recruited based on inclusion criteria and will have to undergo 8 weeks of resistance training the blood samples will be collected for analysis before and after exercise.In this study certain muscle specific biomarkers  like Co Q 10 , Irisin, myostatin, Follistatin, BDNF,P3NP and molecular markers like miRNA specific to muscle miR1/206, miR 21, miR 23a, miR27a,/27b,miR29b-3p, miR 129-5P miR133a-3P, miR 214-5P, miR 486a-5p will be tested and compared . Considering  sarcopenia as a consequence of diabetes mellitus, standard care should be taken as of other complications of diabetes  . Therefore, the need for an accessible panel of biochemical markers that can be measured in blood to identify and monitor sarcopenia is necessary to reduce the burden not only at the individual level but also at the community level.

1 Mesinovic J, Zengin A, De Courten B, Ebeling PR, Scott D. Sarcopenia and type 2 diabetes mellitus: a bidirectional relationship. Diabetes Metab Syndr Obes Targets Ther. 2019;12:1057–72. 

2 D S, B  de C, Pr E. Sarcopenia: a potential cause and consequence of type 2 diabetes in Australia’s ageing population? Med J Aust [Internet]. 2016 Oct 3 [cited 2024 Mar

14];205(7). Available from: https://pubmed.ncbi.nlm.nih.gov/27681976/

3  Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Sarcopenia:

revised European consensus on definition and diagnosis. Age Ageing. 2019 Jan 1;48(1):16–31. 

4  El-Sebaie M, Elwakil W. Biomarkers of sarcopenia: an unmet need. Egypt Rheumatol Rehabil. 2023 Sep 11;50(1):45. 

5   Simaitis S, Schulte-Körne B, Schiffer T, Bloch W, Predel HG, Brixius K, et al. Evidence for Training-Induced Changes in miRNA Levels in the Skeletal Muscle of Patients With Type 2 Diabetes Mellitus. Front Physiol [Internet]. 2020 Dec 3 [cited 2024 Apr 29];11.

6    Drummond MJ, McCarthy JJ, Fry CS, Esser KA, Rasmussen BB. Aging differentially affects human skeletal muscle microRNA expression at rest and after an anabolic stimulus of resistance exercise and essential amino acids. Am J Physiol - Endocrinol Metab. 2008 Dec;295(6):E1333–40.